GET DAILY SIGNALSPharvaris (PHVS) Q3 2026 Earnings Preview: What to Watch
Key Takeaways
- Pharvaris (PHVS) is scheduled to report third-quarter 2026 results on or around November 11, 2026, before the market open, followed by a conference call the next day.
- Consensus estimates call for a net loss of about $0.82 per share, wider than the $0.70 per share loss from the same quarter last year.
- As a clinical-stage biopharmaceutical firm, Pharvaris has minimal or no product revenue, so attention will center on trial updates, operating expenses, and cash position rather than sales figures.
- In the second quarter of 2026, the company reported an $0.81 per share loss that exceeded the roughly $0.74 consensus, and it has beaten estimates in three of the past eight quarters.
- Investors will look for progress on deucrictibant, the oral bradykinin B2 receptor antagonist for hereditary angioedema (HAE), along with any comments on the roughly $364 million cash balance.
Why This Report Matters
Pharvaris focuses on oral treatments for hereditary angioedema, a rare condition marked by sudden swelling attacks. Without an approved product on the market, its quarterly results reflect research spending and clinical milestones more than revenue. I think this update provides a useful check on how effectively the company is using its roughly $364 million cash reserve to move deucrictibant through later-stage studies. After missing estimates last quarter, any signals on trial timing and spending will draw close attention.
What Analysts Expect
Wall Street looks for a net loss near $0.82 per share in the third quarter of 2026, compared with the $0.70 loss posted a year earlier. Revenue forecasts stay low, around $2.35 million, consistent with the pre-commercial stage. The most recent quarter showed an $0.81 per share loss that came in wider than the $0.74 consensus. The company has topped estimates in three of the last eight periods, which highlights the variability typical of early-stage biotech numbers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. With little revenue in view, focus will stay on clinical advances, cost control, and any fresh details on the cash runway.
Market Sentiment Ahead of the Print
Investor mood appears measured. Shares of Pharvaris have risen over the past year, yet the stock has reacted noticeably to past earnings releases, and recent data point to a negative drift afterward. Without product sales to anchor the narrative, the response will probably depend on qualitative commentary about trial schedules, R&D trends, and cash outlook. A larger loss by itself may carry less weight than any shifts in the development story or financing plans.
What Comes Next
After the release, attention will turn to updates on deucrictibant across the HAE programs, especially any changes to late-stage timelines or regulatory steps. Clinical momentum remains the primary long-term value driver for a pre-revenue company. Operating costs and cash burn also warrant monitoring. With roughly $364 million on hand, the balance sheet offers a solid cushion, but faster spending could alter views on future capital needs. Broader biotech sentiment, competitive moves in the HAE space, estimate revisions, and any partnership news could further shape how the market reads the company’s progress.
Integrating AI Tools Into My Process
When reviewing names like Pharvaris, I often turn to Tickeron’s AI Screener to quickly compare technical patterns, fundamentals, and sector trends. It lets me filter thousands of stocks with customizable criteria and surface ideas that might otherwise take hours to identify manually. This kind of scan helps put the current setup in context without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PHVS in upward trend: price rose above 50-day moving average on November 06, 2026
PHVS moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on PHVS as a result. In 98 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PHVS just turned positive on October 20, 2026. Looking at past instances where PHVS's MACD turned positive, the stock continued to rise in 49 of 55 cases over the following month. The odds of a continued upward trend are 89%.
The 10-day moving average for PHVS crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHVS advanced for three days, in 192 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
PHVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for PHVS moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 59 cases where PHVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for PHVS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.026) is normal, around the industry mean (3.498). P/E Ratio (-13.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PHVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement